Filtered By:
Source: Molecular Cancer
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2 results found since Jan 2013.
GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
Conclusions:
Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for patients with mCRPC eliminating its systemic toxicities.
Source: Molecular Cancer - June 19, 2015 Category: Cancer & Oncology Authors: Styliani KaranikaTheodoros KarantanosShinji KurosakaJianxiang WangTakahiro HirayamaGuang YangSanghee ParkAlexei GolstovRyuta TanimotoLikun LiTimothy Thompson Source Type: research
Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia
Conclusions:
Interrupting Vav3 signaling enhances docetaxel-induced apoptosis in LNCaP cells under chronic hypoxia by inhibiting the PI3K/Akt, ERK, and AR signaling pathways. Therapy targeting Vav3 in combination with docetaxel may have practical implications for managing castration-resistant prostate cancer.
Source: Molecular Cancer - April 8, 2013 Category: Cancer & Oncology Authors: Takeo NomuraMutsushi YamasakiKenichi HiraiToru InoueRyuta SatoKeiko MatsuuraMasatsugu MoriyamaFuminori SatoHiromitsu Mimata Source Type: research
